Kleiner Perkins Prepares for Biotech's New Golden Age
This article was originally published in Start Up
Executive Summary
Kleiner Perkins, with two new high-profile partners, Beth Seidenberg and Dana Mead, is betting on applied genomics and personalized medicine, making major investments in molecular diagnostics, stem cell therapies, and drug-device convergence.
You may also be interested in...
The New Service Model for Diagnostics
Amidst a slew of disappointing IPOs, the moderate success of Genomic Health's IPO signals investor interest in a new diagnostics model: a combination product/service business -- technologically agnostic -- focused on coming up with an answer to a specific yes/no question that will either lead to or discourage an expensive therapy by a specialty physician audience. Several other start-ups are following the same model.
UK Stem Cell IPOs Defy Odds
When ReNeuron Ltd. announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a sceptical laugh. But the subsequent IPO, although small, showed that even risky, pre-clinical bets can float--if they're priced low enough.
UK Stem Cell IPOs Defy Odds
When ReNeuron Ltd. announced its intention to float on London's Alternative Investment Market (AIM) in July, most onlookers gave a sceptical laugh. But the subsequent IPO, although small, showed that even risky, pre-clinical bets can float--if they're priced low enough.